Drug discovery
1
drug
With orphan designation
Overview
Congenital pseudoarthrosis of the tibia (CPT) is a rare pediatric bone disorder characterized by anterolateral bowing and spontaneous nonunion of the tibia, often progressing to refractory fractures. Pathogenesis involves abnormal periosteal function, fibrous hamartoma formation, and disrupted bone metabolism, with 50-80% linked to neurofibromatosis type 1. Treatment focuses on achieving bone union while addressing deformities, limb-length discrepancies, and recurrent fractures through multimodal surgical approaches [1][8][15].
Burden
Re-fracture rates up to 14.9% [14], ankle valgus (39.6% [14]), limb-length discrepancies (35.7% [14]), and frequent need for multiple surgeries. Chronic pain, mobility limitations, and psychological impact on families [1][7][15].
(Sources consolidated to reduce citations: [1][3][4][7][8][13][14][15])
Therapies
Surgical: Excision of pseudarthrosis with bone grafting (autograft/vascularized fibular), Ilizarov external fixation [3][15], intramedullary rods [4][13], and cross-union techniques [13].
Adjuncts: Perioperative bisphosphonates, BMP [4][15], and biological augmentation (periosteal grafts [13]).
Salvage: Amputation considered after ≥3 failed surgeries [1][4].
Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases
Drug Discovery Landscape
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
autologous osteogenic cells cultured from adipose tissue derived stem cells embedded in extracellular matrix with demineralized bone matrix. | cell therapies | FDA | 2016-06-30 | — | Novadip Biosciences |